Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Aniracetam vs Saffron: Saffron has the stronger overall evidence (7.5 vs 4/10); they're alternatives for support mood — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Saffron wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Likely helps
5 of 5 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Aniracetam and Saffron have evidence — compare verdict strength side-by-side.
400 mg daily, the dose the cited trials support (they used a single 400 mg dose, or 400 to 600 mg a day where aniracetam was the comparison drug). Label products suggest 750-1,500 mg a day in divided doses, a dose no cited trial used.
With fat-containing food (improves absorption), Divided into 2-3 doses due to short half-life
Aniracetam powder or capsules
28-30mg daily
Morning or split AM/PM
Affron® standardized extract
1-2 weeks
30-60 minutes
1-2 hours
Per dose
4-8 weeks
4-8 weeks
2 menstrual cycles
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study
CNS neuroscience & therapeutics (2012) · Observational · n=276
In patients treated with aniracetam, all studied parameters were adequately maintained at 6 and 12 months, while emotional state was significantly improved at 3 months.
[Clinical study on a randomized, double-blind control of Shenwu gelatin capsule in treatment of mild cognitive impairment]
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007) · Rct · n=166
Double-blind randomised trial in 166 people with mild cognitive impairment, in which aniracetam was the active comparator for the Chinese herbal Shenwu capsule, each taken three times a day for 3 months.
Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis
Psychological medicine (2025) · Meta analysis · n=17437
Hundred and ninety-two trials involving 17,437 patients and 44 nutraceuticals were eligible for inclusion.
Systematic Review and Network Meta-Analysis of the Effects of Plant Extracts on Cognitive Function and Quality of Life in Stroke Patients
Phytotherapy research : PTR (2025) · Meta analysis · n=6599
48 eligible randomized controlled trials were included, covering 6599 stroke patients and evaluating nine different plant extract treatments, one of which was Crocus sativus (saffron).
New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms
Phytotherapy research : PTR (2024) · Systematic review
A random-effects or fixed-effects model was used to calculate the pooled effect sizes.
Both points are doses of a standardised saffron extract (affron) in adults with low mood. A 4-week RCT in 128 adults (PMID 28735826) gave 22 or 28 mg a day: mood improved at 28 mg (POMS total mood disturbance versus placebo, d = -1.10) with no effect at 22 mg. A 12-week RCT in 202 adults with subclinical depressive symptoms (PMID 40414301) confirmed a smaller benefit at 28 mg (DASS-21 depression, d = 0.39). Doses above 28 mg were not compared with lower ones in these trials, so no optimal dose or safety ceiling is plotted. The cited depression meta-analyses pool trials without comparing doses.
AI-estimated from published studies. Interpret as directional guidance.
Saffron has a higher evidence score (7.5/10 vs 4/10) and wins in 2 of 3 categories.
For support mood, Saffron has a higher relevance score (90 vs 50).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
Saffron, EPA omega-3, SAMe have real adjunct evidence — but these aren’t a substitute for care, and some interact dangerously.
Ashwagandha, L-theanine, magnesium, saffron — what actually helps stress, and the safety caveats.
The transition years (40s): cycle changes, mood, sleep, brain fog — foundations, vitex, and starting muscle work early.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.